Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
October 10, 2024 10:28 ET
|
Spherix Global Insights
EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
Lupus Nephritis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034
March 25, 2024 19:42 ET
|
Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Lupus Nephritis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ResearchAndMarkets.com's offering.A...
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
November 09, 2023 16:05 ET
|
Exagen Inc.
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the...
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
November 08, 2023 15:37 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
October 04, 2023 03:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
August 07, 2023 08:35 ET
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
June 28, 2023 07:37 ET
|
ZyVersa Therapeutics
Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damageNLRP3 inflammasomes were extensively activated in...
Lupus Nephritis Treatment Market is expected to accumulate a value of US$ 5.67 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033 | Future Market Insights, Inc.
March 17, 2023 05:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 17, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Lupus Nephritis Treatment Market is expected to grow at a value of 11% CAGR, according to Future Market...
Lupus Nephritis Market Size (2022-2030) Share, Industry Trends, Growth, Challenges and Forecast: Growth Plus Reports
March 02, 2023 07:00 ET
|
Growth Plus Reports
Newark, New Castle, USA, March 02, 2023 (GLOBE NEWSWIRE) -- According to the deep-dive market assessment study by Growth Plus Reports, the global lupus nephritis market was valued at US$ 1.9 billion...